Ezogelin Oflazoglu

Summary

Affiliation: Merck Research Laboratories
Country: USA

Publications

  1. pmc Evolution of anti-CD20 monoclonal antibody therapeutics in oncology
    Ezogelin Oflazoglu
    Merck Bioventures, Discovery Biologics, Merck and Co, Inc, Rahway, NJ, USA
    MAbs 2:14-9. 2010
  2. ncbi Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity
    Svetlana O Doronina
    Seattle Genetics, Inc, 21823 30th Drive SE, Bothell, Washington 98021, USA
    Bioconjug Chem 17:114-24. 2006

Collaborators

  • A F Wahl
  • P D Senter
  • Svetlana O Doronina
  • Charles G Cerveny
  • Roger F Zabinski
  • Damon L Meyer
  • Brian E Toki
  • Tim D Bovee
  • Russell J Sanderson
  • Stephen C Alley
  • Brian A Mendelsohn

Detail Information

Publications2

  1. pmc Evolution of anti-CD20 monoclonal antibody therapeutics in oncology
    Ezogelin Oflazoglu
    Merck Bioventures, Discovery Biologics, Merck and Co, Inc, Rahway, NJ, USA
    MAbs 2:14-9. 2010
    ....
  2. ncbi Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity
    Svetlana O Doronina
    Seattle Genetics, Inc, 21823 30th Drive SE, Bothell, Washington 98021, USA
    Bioconjug Chem 17:114-24. 2006
    ..Thus, alterations of the linker have pronounced impacts on toxicity and lead to new ADCs with greatly improved therapeutic indices...